Akero Therapeutics (NASDAQ:AKRO) Releases Quarterly Earnings Results, Misses Expectations By $0.13 EPS

Share on StockTwits

Akero Therapeutics (NASDAQ:AKRO) released its quarterly earnings results on Tuesday. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.13), Bloomberg Earnings reports.

Shares of AKRO traded down $0.30 on Friday, hitting $19.67. 965 shares of the stock traded hands, compared to its average volume of 66,565. The firm has a 50 day moving average price of $20.41. Akero Therapeutics has a 1 year low of $16.06 and a 1 year high of $30.30.

Separately, Zacks Investment Research lowered shares of Akero Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, October 14th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $31.25.

About Akero Therapeutics

Akero Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development and commercialization of transformative treatments for serious metabolic diseases with high unmet medical need. Its lead product candidate is AKR-001, which completed Phase Ib clinical trial for the treatment of non-alcoholic steatohepatitis disease.

Further Reading: What Are Treasury Bonds?

Receive News & Ratings for Akero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Cronos Group Inc  Given Consensus Rating of “Hold” by Brokerages
Cronos Group Inc Given Consensus Rating of “Hold” by Brokerages
Bicycle Therapeutics Limited  Given Average Recommendation of “Buy” by Analysts
Bicycle Therapeutics Limited Given Average Recommendation of “Buy” by Analysts
The Currency Analytics  Achieves Market Capitalization of $46,977.00
The Currency Analytics Achieves Market Capitalization of $46,977.00
Cable One Inc  Given Average Recommendation of “Hold” by Analysts
Cable One Inc Given Average Recommendation of “Hold” by Analysts
Critical Contrast: Becton Dickinson and  & Oncologix Tech
Critical Contrast: Becton Dickinson and & Oncologix Tech
Zacks: Analysts Expect Amc Networks Inc  to Announce $1.64 Earnings Per Share
Zacks: Analysts Expect Amc Networks Inc to Announce $1.64 Earnings Per Share


© 2006-2019 Ticker Report